Empagliflozin Improves Cardiopulmonary Function and VE/VCO2 in Patients with T2D and HFrEF

Qin, YJ; Acosta, FM; Neppala, S; Cortes, TM; Stepanenko, A; Moody, A; Sanchez, ND; Brown, M; Moreno, LAC; Triplitt, CL; Clarke, GD; Cersosimo, E; Espinoza, SE; Defronzo, RA; Solis-Herrera, C

DIABETES, 2023; 72 ():